Among other findings, Deloitte statistics show that 45 per cent of Canadian biotechnology companies got funding from government programs in 2017, and of those, 80 per cent got funds through the Scientific Research and Experimental Development Program. Image courtesy of Pixabay
Open science partnerships are breaking the traditional pathways of research and development. While not a panacea, they pose a unique and exciting made-in-Canada solution to our pressing productivity challenges.
At present, there is no discernible evidence of a cross-cutting or all-of-government strategy to increase the commercial dividends from the scientific capital we have accumulated in the biological sciences.